B cells as a therapeutic target in autoimmune disease

Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid ar...

Full description

Bibliographic Details
Main Authors: Goronzy, Jörg J, Weyand, Cornelia M
Format: Online
Language:English
Published: BioMed Central 2003
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165047/

Similar Items